Cannabis Components and SARS-CoV-2: A Promising Study
Read time: 1 Minutes
Created By: Nate Abegglen | Posted: 01-14-22
If you haven't already seen the stories circulating, a study was recently published from a research team affiliated with Oregon State University that showed promise in certain cannabis compound inhibiting the virus that causes Covid 19's ability to bind with human cells. The title of this study is, "“Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants."
The compounds in particular studied here are cannabigerolic acid, or CBGA, and cannabidiolic acid, also known as CBDA. How do they accomplish this? They found that these two cannabinoids had the ability to bind with the spike proteins of the virus, which then inhibited the virus' ability to subsequently bind and enter human cells.
You also may be wondering what "CBDA" and "CBGA" are. These two compounds of the hemp plant are essentially "raw" forms of cannabinoids that you are more aware of, like CBD, CBG, CBN, THC, etc.
The raw, acid forms (CBDA and CBGA, in this case) can transform into non-acid forms through a heating process called decarboxylation, which is generally a part of the extraction of cannabinoids from the hemp plant. The acid forms are most prevalent, naturally, in full spectrum hemp extract, which is something we specialize in at Kannaco.
Stated in the Abstract of the study, "As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19." This is just one step in fighting the virus that causes Covid-19, but a very exciting development indeed, and another reason we are a proud part of the hemp community!
Your cart is empty
(Let's fix that)Shop CBD